Biography for Damian Garde
Damian Garde, Editor
Damian is an editor with Fierce's life sciences publications, writing for FierceBiotech, FierceMedicalDevices and FierceCRO. Prior to joining Fierce, he worked for Patch.com in Maryland, and The Albuquerque Journal and Weekly Alibi in Albuquerque, NM. Damian lives in Washington, DC, and considers himself the foremost Carmelo Anthony apologist in the greater metropolitan area. You can email him at email@example.com and follow @DamianFierce on Twitter.
Articles by Damian Garde
Months after LabCorp acquired its rival Covance, Quintiles has signed a sweeping agreement with lab testing giant Quest Diagnostics to launch a joint venture focused on clinical trials.
CRO giant Parexel International is acquiring an Indian company devoted to pharmacovigilance, looking to expand its share of the global market for managing drug safety data.
Contract drug developer Recipharm has inked a deal with Adroit Science to join forces in drug formulation.
U.K. contractor Ergomed has made Asian landfall, opening an office in Taiwan with eyes on forging traditional CRO deals and signing risk-sharing agreements with drugmakers.
Clinical trial service provider BioClinica is stretching out in the biopharma hotbed of Research Triangle Park, NC, opening a new operation to play a bigger role in drug development in the region.
When patients sign up for a clinical trial, how well do they understand the risks, requirements and restrictions that come with it? Icon, a global CRO that handles thousands of studies a year, is working with behavioral scientists at Carnegie Mellon University to study how investigators can improve the informed consent process.
Quintiles, the world's largest CRO, has reached out to startup Tute Genomics for access to its database of 8.5 billion annotations of genetic variants.
Clinical Ink, a provider of trial data software, is merging with Boston's CentrosHealth in hopes of expanding its platform for paperless studies.
PPD's Acurian subsidiary has expanded its relationship with the Society for Clinical Research Sites, a group representing thousands of trial outposts around the globe, focusing on improving patient recruitment.
Catalent is merging a few of its core business units in hopes of better focusing on getting its clients' drugs onto the market and pulling off smooth launches.